本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

38.57
+0.17000.44%
盘后38.570.00000.00%18:07 EDT
成交量:316.80万
成交额:1.22亿
市值:73.24亿
市盈率:-10.91
高:39.16
开:38.85
低:38.12
收:38.40
数据加载中...
2024/05/02

重要事件披露

Form 8-K - Current report
2024/03/06

重要事件披露

Form 8-K - Current report
2024/03/04

重要事件披露

Form 8-K - Current report
2024/02/22

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/22

重要事件披露

Form 8-K - Current report
2024/02/16

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/18

重要事件披露

Form 8-K - Current report
2024/01/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/09

重要事件披露

Form 8-K - Current report
2024/01/06

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/12/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities